🎉 M&A multiples are live!
Check it out!

TYK Medicines Valuation Multiples

Discover revenue and EBITDA valuation multiples for TYK Medicines and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

TYK Medicines Overview

About TYK Medicines

TYK Medicines Inc is a drug discovery research and development centre. The company and its subsidiaries are principally engaged in the research, development and commercialization of pharmaceutical products.


Founded

2017

HQ

Hong Kong
Employees

147

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$1.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

TYK Medicines Financials

TYK Medicines has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, TYK Medicines achieved revenue of n/a and an EBITDA of -$44.6M.

TYK Medicines expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See TYK Medicines valuation multiples based on analyst estimates

TYK Medicines P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.7M n/a XXX XXX XXX
Gross Profit n/a $2.6M XXX XXX XXX
Gross Margin NaN% Infinity% XXX XXX XXX
EBITDA -$37.6M -$44.6M XXX XXX XXX
EBITDA Margin -660% -Infinity% XXX XXX XXX
Net Profit n/a -$40.0M XXX XXX XXX
Net Margin NaN% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

TYK Medicines Stock Performance

As of April 15, 2025, TYK Medicines's stock price is HKD 26 (or $3).

TYK Medicines has current market cap of HKD 9.8B (or $1.3B), and EV of HKD 9.5B (or $1.2B).

See TYK Medicines trading valuation data

TYK Medicines Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.2B $1.3B XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

TYK Medicines Valuation Multiples

As of April 15, 2025, TYK Medicines has market cap of $1.3B and EV of $1.2B.

TYK Medicines's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate TYK Medicines's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for TYK Medicines and 10K+ public comps

TYK Medicines Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.2B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -27.5x XXX XXX XXX
P/E -25.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -34.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TYK Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

TYK Medicines Valuation Multiples

TYK Medicines's NTM/LTM revenue growth is n/a

TYK Medicines's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.2M for the same period.

Over next 12 months, TYK Medicines's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate TYK Medicines's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for TYK Medicines and other 10K+ public comps

TYK Medicines Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

TYK Medicines Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

TYK Medicines M&A and Investment Activity

TYK Medicines acquired  XXX companies to date.

Last acquisition by TYK Medicines was  XXXXXXXX, XXXXX XXXXX XXXXXX . TYK Medicines acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by TYK Medicines

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About TYK Medicines

When was TYK Medicines founded? TYK Medicines was founded in 2017.
Where is TYK Medicines headquartered? TYK Medicines is headquartered in Hong Kong.
How many employees does TYK Medicines have? As of today, TYK Medicines has 147 employees.
Is TYK Medicines publicy listed? Yes, TYK Medicines is a public company listed on HKG.
What is the stock symbol of TYK Medicines? TYK Medicines trades under 02410 ticker.
When did TYK Medicines go public? TYK Medicines went public in 2024.
Who are competitors of TYK Medicines? Similar companies to TYK Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of TYK Medicines? TYK Medicines's current market cap is $1.3B
Is TYK Medicines profitable? Yes, TYK Medicines is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.